Sign in
CompletedPhase 2

Addressing Heavy Alcohol Use Consumption With Kudzu

Key facts

Who runs it
Glenn-Milo Santos
Where
San Francisco, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
120 people enrolled
Started
11 Jul 2019
Ended
1 Jun 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Standardized kudzu
  • Placebo
  • Sexually transmitted infection testing:
  • Medical Management (MM) counseling for alcohol use:
  • Urinalysis for novel alcohol biochemical markers for recent alcohol use:
  • Dried Blood Spot (DBS) Testing for PEth:
  • Behavioral survey measurements:
  • Ecological Momentary Assessment procedure:
Record updated
1 May 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Self-reported anal or vaginal sex in the prior three months while under the influence of alcohol, or reported missing ART or PrEP due to alcohol use in the prior 3 months
  • at least one binge-drinking (five or more drinks on a single occasion for men; four or more drinks for women) session per week in the prior three months
  • having an AUD by DSM-5 SCID criteria (includes hazardous and harmful use)
  • interested in reducing binge alcohol consumption
  • HIV negative by rapid antibody test and HIV pooled RNA test; or HIV positive with a medical record documentation of HIV infection.* For HIV-positive individuals, having a CD4 cell count >100 cells/mm3 and having suppressed HIV viral load with < 50 copies/mm3; *
  • no current acute illnesses requiring prolonged medical care
  • no chronic illnesses that are likely to progress clinically during trial participation
  • able and willing to provide informed consent and adhere to visit schedule
  • age 18-70 years
  • baseline CBC, total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, and electrolytes without clinically significant abnormalities as determined by study clinician in conjunction with symptoms, physical exam, and medical history; (*Note: Participants newly diagnosed with HIV at screening are eligible for the study but we will postpone their enrollment until they are virally suppressed with HIV viral load < 50 copies/mm .)

Who cannot take part

  • known allergy/previous adverse reaction to kudzu
  • Any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation in the study
  • current severe substance-use disorder (exclusive of nicotine, cannabis or alcohol) as determined by DSM-V SCID criteria
  • HIV positive individuals who are not virally suppressed
  • any condition that, in the principal investigator and/or study clinician's judgment interferes with safe study participation or adherence to study procedures
  • moderate/severe liver disease (AST, ALT > 5 times upper limit of normal)
  • impaired renal function (creatinine clearance < 50 ml/min)
  • not willing to learn how to send EMA surveys; (*Note: Eligible participants who have a partner currently in the study will be enrolled and randomized after their partner has completed their in-treatment follow-up, to reduce the concerns of contamination between treatment conditions. Additionally, we will exclude individuals with impaired renal function as a general precaution. Pharmacokinetic data on kudzu is limited. Puerarin is present in the urine of rats for 4-72 hours after oral administration, thus there is renal elimination of the active compound, as well as it's metabolite, equol. For this reason, we prefer to be cautious by limiting enrollment to those with reasonable renal function. We selected eGFR < 50mL/min as that is the level at which most products with renal clearance begin to demonstrate risks of increased toxicity.)
  • currently participating in another intervention research study with potential overlap
  • pregnant women

Where in United States

  • San Francisco Department of Public HealthSan Francisco, United States

About the trial

What the trial wants to find out

Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol use and alcohol-associated sexual behaviors among sexually-active, binge-drinking individuals at high risk for HIV infection.

The 2 groups in the trial

  • KudzuTreatment being tested

    Standardized kudzu

    Treatment: Standardized kudzu, Sexually transmitted infection testing:, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers for recent alcohol use:, Dried Blood Spot (DBS) Testing for PEth:, Behavioral survey measurements:, and Ecological Momentary Assessment procedure:

  • ControlPlacebo, for comparison

    Placebo

    Treatment: Placebo, Sexually transmitted infection testing:, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers for recent alcohol use:, Dried Blood Spot (DBS) Testing for PEth:, Behavioral survey measurements:, and Ecological Momentary Assessment procedure:

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A-HACK Project: Addressing Heavy Alcohol Use Consumption With Kudzu
Publications
Record updated
1 May 2026